Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction.

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer.

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS).

COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer's Disease.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.